Frequently asked questions about BPC 157 for immune support Do you still have unanswered questions
Semaglutide is not known to harm kidney function in most people, and in fact, it may help protect kidneys in diabetic patients by improving blood sugar control
Preclinical research indicates GHK-Cu may extend this phase, but equivalent human evidence is lacking
Practical take For clinicians, this reinforces a more nuanced approach: Match the drug to the patient profile Look beyond average weight loss alone Consider tolerability, adherence, comorbidities, access, and long-term strategy The obesity pipeline is getting deeperand that is good news for patients
The scientists found that semaglutide had a positive impact on the symptoms, physical limitations, and body weight of people with HFpEF regardless of their use of diuretics
The goal is not simply losing pounds on the scale